References

Unresolved reference

2019 · External reference

Community health and prevention: It takes a village to reduce cardiovascular risk! Let us do it together!

10.1177/2047487319867505 · 2019 · External reference

Ageing as a risk factor for neurodegenerative disease

10.1038/s41582-019-0244-7 · 2019 · External reference

Neurodegenerative diseases

2011 · External reference

Hallmarks of neurodegenerative diseases

10.1016/j.cell.2022.12.032 · 2023 · External reference

Unresolved reference

2014 · External reference

The impact of age on cognition

10.1055/s-0035-1555115 · 2015 · External reference

Cognitive impairment and its associated factors in older adults living in high and low altitude areas: a comparative study

10.3389/fpsyt.2022.871414 · 2022 · External reference

How the cognitive status of older people affects their care dependency level and needs: a cross-sectional study

10.3390/ijerph191610257 · 2022 · External reference

Mild cognitive impairment and dementia: the importance of modifiable risk factors

2011 · External reference

Alzheimer’s therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond?

10.1016/j.bcp.2012.11.014 · 2013 · External reference

Advances in management of neuropsychiatric syndromes in neurodegenerative diseases

10.1007/s11920-019-1058-4 · 2019 · External reference

Strategies of engineering nanoparticles for treating neurodegenerative disorders

10.2174/1389200218666170125114751 · 2017 · External reference

Novel targets and therapies of metformin in dementia: old drug, new insights

10.3389/fphar.2024.1415740 · 2024 · External reference

Metformin: from mechanisms of action to therapies

10.1016/j.cmet.2014.09.018 · 2014 · External reference

Diagnosis and classification of diabetes: standards of care in diabetes-2024

2023 · External reference

Clinical efficacy and cost-effectiveness of metformin in different patient populations: a narrative review of real-world evidence

10.1111/dom.15729 · 2024 · External reference

Metformin: beyond type 2 diabetes mellitus

2024 · External reference

Metformin improves performance in high-intensity exercise, but not anaerobic capacity in healthy male subjects

10.1111/1440-1681.12474 · 2015 · External reference

Acute metformin administration increases mean power and the early Power phase during a Wingate test in healthy male subjects

10.1080/17461391.2021.1930191 · 2022 · External reference

Acute metformin intake on exercise performance in healthy participants during functional fitness training

2025 · External reference

View on metformin: antidiabetic and pleiotropic effects, pharmacokinetics, side effects, and sex-related differences

10.3390/ph17040478 · 2024 · External reference

Metformin prevents NDEA-induced memory impairments associated with attenuating beta-amyloid, tumor necrosis factor-alpha, and interleukin-6 levels in the hippocampus of rats

10.3390/biom13091289 · 2023 · External reference

Mito-metformin protects against mitochondrial dysfunction and dopaminergic neuronal degeneration by activating upstream PKD1 signaling in cell culture and MitoPark animal models of Parkinson’s disease

10.3389/fnins.2024.1356703 · 2024 · External reference

Exploring the pharmacological potential of metformin for neurodegenerative diseases

10.3389/fnagi.2022.838173 · 2022 · External reference

Metformin: the winding path from understanding its molecular mechanisms to proving therapeutic benefits in neurodegenerative disorders

10.3390/ph16121714 · 2023 · External reference

Highlighting the protective or degenerative role of AMPK activators in dementia experimental models

10.2174/1871527320666210526160214 · 2021 · External reference

Promising use of metformin in treating neurological disorders: biomarker-guided therapies

10.4103/1673-5374.385286 · 2024 · External reference

Promising use of metformin in treating neurological disorders: biomarker-guided therapies

10.4103/1673-5374.385286 · 2024 · External reference

Diabetic patients treated with metformin during early stages of Alzheimer’s disease show a better integral performance: data from ADNI study

10.1007/s11357-022-00568-6 · 2022 · External reference

Metformin use is associated with slowed cognitive decline and reduced incident dementia in older adults with type 2 diabetes: the Sydney Memory and Ageing Study

10.2337/dc20-0892 · 2020 · External reference

Metformin, age-related cognitive decline, and brain pathology

10.1016/j.neurobiolaging.2023.10.005 · 2024 · External reference

Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer’s disease, and the role APOE carrier status

10.1002/alz.12161 · 2020 · External reference

Deciphering the roles of metformin in Alzheimer’s disease: a snapshot

10.3389/fphar.2021.728315 · 2022 · External reference

The effect of metformin on cognitive function: a systematic review and meta-analysis

10.1177/02698811211057304 · 2022 · External reference

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

10.1016/j.ijsu.2021.105906 · 2021 · External reference

Rayyan-a web and mobile app for systematic reviews

10.1186/s13643-016-0384-4 · 2016 · External reference

Literature searches in systematic reviews and meta-analyses: a review, evaluation, and recommendations

10.1016/j.jvb.2020.103377 · 2020 · External reference

Unresolved reference

2014 · External reference

Unresolved reference

2017 · External reference

Factors associated with low health literacy in unpaid caregivers of older people: a systematic review

10.1093/heapro/daae118 · 2024 · External reference

Psychological concerns associated with empathy in paid and unpaid caregivers of older people: a systematic review

10.1080/07317115.2022.2090879 · 2024 · External reference

Unresolved reference

1988 · External reference

Meta-analysis in clinical trials

10.1016/0197-2456(86)90046-2 · 1986 · External reference

Operating characteristics of a rank correlation test for publication bias

10.2307/2533446 · 1994 · External reference

Bias in meta-analysis detected by a simple, graphical test

10.1136/bmj.315.7109.629 · 1997 · External reference

Effects of vildagliptin, a DPP-4 inhibitor, in elderly diabetic patients with mild cognitive impairment

10.1016/j.archger.2019.06.001 · 2019 · External reference

The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer’s disease

10.1016/j.diabres.2016.12.010 · 2017 · External reference

Taking metformin and cognitive function change in older patients with diabetes

10.1111/ggi.13692 · 2019 · External reference

Cognitive impairment in frail hypertensive elderly patients: role of hyperglycemia

10.3390/cells10082115 · 2021 · External reference

Prediabetes increases the risk of frailty in prefrail older adults with hypertension: beneficial effects of metformin

10.1161/hypertensionaha.124.23087 · 2024 · External reference

Metformin use and cognitive function in older adults with type 2 diabetes following a Mediterranean diet intervention

10.3389/fnut.2021.742586 · 2021 · External reference

Long-term use of metformin is associated with reduced risk of cognitive impairment with alleviation of cerebral small vessel disease burden in patients with type 2 diabetes

10.3389/fnagi.2021.773797 · 2021 · External reference

Association of metformin, sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer’s disease: Pooled analysis from 5 cohorts

10.1371/journal.pone.0212293 · 2019 · External reference

The association between metformin use and risk of developing severe dementia among AD patients with type 2 diabetes

10.3390/biomedicines11112935 · 2023 · External reference

Effects of vildagliptin, a DPP-4 inhibitor, in elderly diabetic patients with mild cognitive impairment

10.1016/j.archger.2019.06.001 · 2019 · External reference

Underlying mechanisms of brain aging and neurodegenerative diseases as potential targets for preventive or therapeutic strategies using phytochemicals

10.3390/nu15153456 · 2023 · External reference

Neural ageing and synaptic plasticity: prioritizing brain health in healthy longevity

10.3389/fnagi.2024.1428244 · 2024 · External reference

Cognitive decline in ageing and disease: Risk factors, genetics and treatments

2024 · External reference

Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus

10.1136/bmjopen-2018-024954 · 2019 · External reference

Neuro-protective role of metformin in patients with acute stroke and type 2 diabetes mellitus via AMPK/mammalian target of rapamycin (mTOR) signaling pathway and oxidative stress

10.12659/msm.911250 · 2019 · External reference

Peripheral inflammation and insulin resistance: their impact on blood-brain barrier integrity and glia activation in Alzheimer’s disease

10.3390/ijms26094209 · 2025 · External reference

The mechanism and treatment of cognitive dysfunction in diabetes: a review

10.1055/a-2480-7826 · 2025 · External reference

Beneficial effects of metformin treatment in hyperglycaemic patients affected by ischaemia with no obstructive coronary artery

10.1093/cvr/cvae269 · 2024 · External reference

AMPK--sensing energy while talking to other signaling pathways

10.1016/j.cmet.2014.09.013 · 2014 · External reference

Metformin mitigates trimethyltin-induced cognition impairment and hippocampal neurodegeneration

10.1007/s10571-024-01502-4 · 2024 · External reference

Unravelling shared pathways linking metabolic syndrome, mild cognitive impairment, dementia, and sarcopenia

10.3390/metabo15030159 · 2025 · External reference

Medications and cognitive decline in Alzheimer’s disease: cohort cluster analysis of 15,428 patients

10.1177/13872877241307870 · 2025 · External reference

Metformin protects from rotenone-induced nigrostriatal neuronal death in adult mice by activating AMPK-FOXO3 signaling and mitigation of angiogenesis

10.3389/fnmol.2020.00084 · 2020 · External reference

Metformin-induced changes in the gut microbiome and plasma metabolome are associated with cognition in men

10.1016/j.metabol.2024.155941 · 2024 · External reference

Metformin normalizes mitochondrial function to delay astrocyte senescence in a mouse model of Parkinson’s disease through Mfn2-cGAS signaling

10.1186/s12974-024-03072-0 · 2024 · External reference

Metformin activates chaperone-mediated autophagy and improves disease pathologies in an Alzheimer disease mouse model

10.1007/s13238-021-00858-3 · 2021 · External reference

Incident dementia risk among patients with type 2 diabetes receiving metformin versus alternative oral glucose-lowering therapy: an observational cohort study using UK primary healthcare records

10.1136/bmjdrc-2023-003548 · 2024 · External reference

Individual and combined associations of glucose metabolic components with cognitive function modified by obesity

10.3389/fendo.2021.769120 · 2021 · External reference

Extended-release metformin improves cognitive impairment in frail older women with hypertension and diabetes: preliminary results from the LEOPARDESS study

10.1186/s12933-023-01817-4 · 2023 · External reference

Association of metformin use with Alzheimer’s disease in patients with newly diagnosed type 2 diabetes: a population-based nested case-control study

10.1038/s41598-021-03406-5 · 2021 · External reference

Long-term metformin usage and cognitive function among older adults with diabetes

10.3233/jad-131901 · 2014 · External reference

Metformin use is associated with a reduced risk of cognitive impairment in adults with diabetes mellitus: a systematic review and meta-analysis

10.3389/fnins.2022.984559 · 2022 · External reference

The potential effect of metformin on cognitive and other symptom dimensions in patients with schizophrenia and antipsychotic-induced weight gain: a systematic review, meta-analysis, and meta-regression

10.3389/fpsyt.2023.1215807 · 2023 · External reference

Beneficial effects of metformin treatment on memory impairment

10.1007/s11033-024-09445-1 · 2024 · External reference

Metformin improves cognitive impairment in patients with schizophrenia: associated with enhanced functional connectivity of dorsolateral prefrontal cortex

10.1038/s41398-023-02616-x · 2023 · External reference

The mechanism and treatment of cognitive dysfunction in diabetes: a review

10.1055/a-2480-7826 · 2025 · External reference